Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
10.12.2021 09:15:00 EET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.
Hervé Gisserot, a French citizen, is an experienced industry executive and has a proven track record of building and leading organizations across the U.S., Europe and Asia Pacific with extensive launch and market access experiences. He joins from GlaxoSmithKline where he served in multiple Senior Vice President roles in the last 13 years. He is a graduate of the Institute of Political Science Paris (IEP), and has completed the General Management program at INSEAD.
With this new appointment, the President US, the Regional Commercial Heads, the Rare Disease BU, the central commercial, marketing and pricing teams, will report to the Chief Commercial Officer. This is to lead the organization ahead of expected approvals and subsequent launches of four pipeline products in the next 18 months, and to maximize opportunities of our iron portfolio.
Abbas Hussain, Chief Executive Officer of Vifor Pharma Group, commented: “I am delighted that Hervé joins Vifor Pharma. He brings a wealth of commercial experience from leading pharmaceutical companies at an international level, delivering profitable growth across multiple therapeutic areas and markets. His professional background makes him ideally suited to lead the commercial organization and to put a strong focus on execution as we accelerate growth to become a multi-brand organization focused on in-licensing, partnering and commercializing products worldwide.”
Photo:
A picture of Hervé Gisserot is available for download at viforpharma.com/media/media-library
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005908/en/
Contact information
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Invivoscribe ® Expands IVDR Portfolio with IdentiClone ® Dx IGH Assay Certification26.3.2026 07:13:00 EET | Press release
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis and patient management. BSI (Netherlands), an EU-designated Notified Body, granted CE certification for the IdentiClone Dx IGH Assay following an independent conformity assessment un
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium26.3.2026 00:22:00 EET | Press release
The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and Midas Dominicana, a Dominican business group specializing in the comprehensive management of technology projects in the region. Together, both companies will guarantee the delivery of a passport that is more secure, reliable, and compliant with international standards. The project introduces and personalizes the country’s electronic passports, using advanced technologies to ensure the authenticity and protection of each document, while strengthening the national i
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium26.3.2026 00:22:00 EET | Press release
The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and Midas Dominicana, a Dominican business group specializing in the comprehensive management of technology projects in the region. Together, both companies will guarantee the delivery of a passport that is more secure, reliable, and compliant with international standards. The project introduces and personalizes the country’s electronic passports, using advanced technologies to ensure the authenticity and protection of each document, while strengthening the national i
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium26.3.2026 00:22:00 EET | Press release
The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and Midas Dominicana, a Dominican business group specializing in the comprehensive management of technology projects in the region. Together, both companies will guarantee the delivery of a passport that is more secure, reliable, and compliant with international standards. The project introduces and personalizes the country’s electronic passports, using advanced technologies to ensure the authenticity and protection of each document, while strengthening the national i
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 18:20:00 EET | Press release
3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Systems’ largest potential new product launches: the NextDent® Jetted Denture Solution. This solution forms the cornerstone of the Company’s ‘replac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom